Begins commercial shipments of Xenium
Cell Segmentation Kit to improve determination of cell
boundaries
Launches first Xenium application-focused
panel optimized for immuno-oncology across all tissue types
PLEASANTON, Calif.,
March 21, 2024 /PRNewswire/ -- 10x
Genomics, Inc. (Nasdaq: TXG), a leader in single cell and spatial
biology, announced today the commercial availability of its Xenium
multi-modal cell segmentation kit and the launch of a new Xenium
gene panel optimized for immuno-oncology applications. These new
products expand the breadth of the Xenium single cell spatial
analysis menu.
"We built Xenium to be the best performing platform for in situ
analysis, not only at launch, but for the long term," said
Michael Schnall-Levin, Founding
Scientist and Chief Technology Officer at 10x Genomics. "These new
products are a testament to how we listen closely to our customers
to build products that are most responsive to their needs. We have
several more launches planned for Xenium this year, as we continue
to innovate, enhance and expand our menu of high-performing Xenium
assays to help customers answer their specific research
questions."
Xenium In Situ Cell Segmentation Kit
The Xenium In
Situ Cell Segmentation Kit improves the determination of cell
boundaries by using a stain and algorithmic technique developed and
validated through custom-trained machine learning models. Key
features:
- Precise cell segmentation: Use multiple morphological
features and a purpose-built algorithm for data-driven,
high-confidence transcript-to-cell assignments.
- Diverse stains for comprehensive coverage: Easily
capture and visualize tissue architecture in four channels from
epithelial and stromal cells, to immune markers, to cell interiors
and nuclei.
- State-of-the-art, custom-built algorithm: Obtain more
accurate cell segmentation with an advanced AI algorithm
specifically trained on real-world Xenium cellular and tissue
data.
- Immediate access to data: Get interpretation-ready data
as soon as the Xenium run is done in open formats that enable
seamless compatibility with third-party tools.
- Seamless workflow integration and broad tissue and sample
compatibility: Cover heterogeneous cell types and tissues in
human and mouse samples with a single multi-tissue cocktail,
without the need to switch stains for different applications or
tissue types. Validated on fresh frozen and FFPE tissues.
"While Xenium launched with a robust nuclear-based segmentation
approach, we've built our new solution from the ground up to
improve segmentation accuracy," added Schnall-Levin. "This solution
not only enables researchers to more effectively call cell types,
but it also gives more confidence that transcriptomic data is
attributed to the correct cell of origin for the most accurate
biological interpretation."
Quan Nguyen, Group Leader at the
University of Queensland, said, "We
have evaluated several computational methods to enhance cell
membrane segmentation across various technologies. We found that
the experimental data obtained from Xenium membrane staining
consistently yields the most accurate segmentation results, leading
to improved downstream analysis of cell types and cell-to-cell
interactions. We will use this kit in many of our coming Xenium
experiments."
Xenium Immuno-Oncology Panel
The Xenium
Immuno-Oncology Panel is a comprehensive solution for unraveling
the dynamic interplay between tissue biology, tumor biology and
immunology. The first application-focused panel on Xenium, this
assay is the latest addition to a broad menu of expertly curated
and customizable gene panels optimized for specific tissue types
and disease states. Key features:
- Unlock intricate details of the tumor microenvironment:
Get extensive detection of diverse immune cell types and states,
including their migration, regulation and function, allowing for a
deeper understanding of the immune landscape within the tumor
microenvironment.
- Analyze a variety of cancer types: Examine a broad
spectrum of cancer types and tumor biology through the
identification of tumor-specific markers, oncogenes, checkpoint
proteins and mechanisms of immune evasion, providing insights for
the development of targeted therapy strategies.
- Customizable panels: Expand the 380-plex pre-designed
panel with up to 100 additional custom genes, enabling a tailored
and cost-effective assay.
The Xenium Immuno-Oncology Panel is compatible with both fresh
frozen and FFPE tissues, ensuring flexibility and reliable
performance across various sample types. It is available for
pre-order and is expected to ship this month.
About 10x Genomics
10x Genomics is a life science
technology company building products to accelerate the mastery of
biology and advance human health. Our integrated solutions include
instruments, consumables and software for single cell and spatial
biology, which help academic and translational researchers and
biopharmaceutical companies understand biological systems at a
resolution and scale that matches the complexity of biology. Our
products are behind breakthroughs in oncology, immunology,
neuroscience and more, fueling powerful discoveries that are
transforming the world's understanding of health and disease. To
learn more, visit 10xgenomics.com or connect with
us on LinkedIn or X (Twitter).
Forward Looking Statements
This press release contains
forward-looking statements within the meaning of the Private
Securities Litigation Reform Act of 1995 as contained in Section
27A of the Securities Act of 1933, as amended, and Section 21E of
the Securities Exchange Act of 1934, as amended, which fall under
the "safe harbor" provisions of those sections. All statements,
other than statements of historical facts, may be forward-looking
statements. Forward-looking statements generally can be identified
by the use of forward-looking terminology such as "may," "might,"
"will," "should," "expect," "plan," "anticipate," "could,"
"intend," "target," "project," "contemplate," "believe,"
"estimate," "predict," "potential" or "continue" or variations of
them or similar terminology, but the absence of these words does
not mean that a statement is not forward-looking. These
forward-looking statements include statements regarding 10x
Genomics, Inc.'s ("10x Genomics") product launches, performance,
configuration, capabilities, adoption and pipeline. These
statements are based on management's current expectations,
forecasts, beliefs, assumptions and information currently available
to management, and actual outcomes and results could differ
materially from these statements due to a number of factors. Other
risks and uncertainties that could affect 10x Genomics' financial
and operating results and cause actual results to differ materially
from those indicated by the forward-looking statements made in this
press release include those discussed under the captions "Risk
Factors" and "Management's Discussion and Analysis of Financial
Condition and Results of Operations" and elsewhere in the documents
10x Genomics files with the Securities and Exchange Commission (the
"SEC") from time to time. Although 10x Genomics believes that the
expectations reflected in the forward-looking statements are
reasonable, it cannot provide any assurance that these expectations
will prove to be correct nor can it guarantee that the future
results, levels of activity, performance and events and
circumstances reflected in the forward-looking statements will be
achieved or occur. The forward-looking statements in this press
release are based on information available to 10x Genomics as of
the date hereof, and 10x Genomics disclaims any obligation to
update any forward-looking statements provided to reflect any
change in its expectations or any change in events, conditions or
circumstances on which any such statement is based, except as
required by law. These forward-looking statements should not be
relied upon as representing 10x Genomics' views as of any date
subsequent to the date of this press release.
Disclosure Information
10x Genomics uses filings with
the Securities and Exchange Commission, our website
(www.10xgenomics.com), press releases, public conference calls,
public webcasts and our social media accounts as means of
disclosing material non-public information and for complying with
our disclosure obligations under Regulation FD.
Contacts
Investors: investors@10xgenomics.com
Media: media@10xgenomics.com
View original content to download
multimedia:https://www.prnewswire.com/news-releases/10x-genomics-expands-xenium-menu-with-multi-modal-cell-segmentation-kit-and-immuno-oncology-gene-panel-302096366.html
SOURCE 10x Genomics, Inc